The Bio-Pharmacology Team at Mother's Pharmaceuticals is committed to the development of new drugs to address musculoskeletal, diabetes, and obesity diseases. The ultimate goal is to produce first-in-class global drugs that can meet unmet needs in these therapeutic areas. To achieve this goal, the team conducts thorough evaluations of efficacy, toxicity, and ADME parameters in order to develop drugs that are not only more effective than existing products but also exhibit minimal toxicity. The company invests substantially in the pursuit of innovative therapies and continuously identifies and develops promising projects with a high likelihood of success. Furthermore, it is pursuing a global expansion strategy through both domestic and international licensing efforts.

The Formulation Research Team is responsible for conducting research on new drugs, incrementally modified drugs, and generics, including their formulation and processes. Leveraging proprietary technology, the team is developing advanced products that enhance patient adherence and convenience while reducing side effects. Additionally, the team is conducting process research to ensure the flawless production of the developed pharmaceuticals.

The CMC Team compiles regulatory documents for pharmaceutical products intended for domestic and international exports. They prepare CTD data tailored to ICH guidelines and specific national requirements. Additionally, the team manages schedules to ensure that there are no delays in approvals, aligning with launch timelines for new drugs.

The CMC team compiles regulatory documents for pharmaceutical products intended for domestic and international exports. They prepare CTD data tailored to ICH guidelines and specific national requirements. Additionally, the team manages schedules to ensure that there are no delays in approvals, aligning with launch timelines for new drugs.